|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
6.730 USD |
+7.00% | +12.64% | -16.29% | |
Published on 05/17/2025 at 22:15
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears |
May. 08 |
RE |
|
Health Care Down on Cyclical Bias — Health Care Roundup |
May. 08 |
DJ |
|
Sector Update: Health Care Stocks Softer Late Afternoon |
May. 08 |
MT |
|
Sector Update: Health Care Stocks Decline Thursday Afternoon |
May. 08 |
MT |
|
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears |
May. 08 |
RE |
|
Novavax Shares Rise After Swinging to Q1 Profit |
May. 08 |
MT |
|
Novavax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 08 |
CI |
|
Novavax, Inc., Q1 2025 Earnings Call, May 08, 2025 |
May. 08 |
|
|
Earnings Flash (NVAX) NOVAVAX INC. Posts Q1 Revenue $667M, vs. FactSet Est of $91.7M |
May. 08 |
MT |
|
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 |
May. 07 |
RE |
|
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 |
May. 07 |
RE |
|
Novavax To Receive $19.5 Million Upfront Payment Under Amended Agreement With Takeda |
May. 05 |
RE |
|
Novavax, Inc. Enter into A Collaboration and Exclusive License Agreement, as Amended, with Takeda Pharmaceutical Company Limited |
May. 05 |
CI |
|
Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan |
May. 05 |
MT |
|
B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating |
May. 05 |
MT |
|
Novavax Announces Improved Terms For Collaboration, License Agreement With Takeda For Nuvaxovid In Japan |
May. 05 |
RE |
|
Moderna says FDA has been constructive, but delays flu/COVID shot |
May. 01 |
RE |
|
Novavax Appoints Charles Newton To Board Of Directors |
Apr. 29 |
RE |
|
Novavax Appoints Charles Newton To Board Of Directors |
Apr. 29 |
RE |
|
Novavax, Inc. Appoints Charles Newton to Its Board as an Independent Director |
Apr. 29 |
CI |
|
Novavax Board Of Directors Appreciates The Formal Support And Strategic Guidance Of Shah Capital |
Apr. 28 |
RE |
|
Health Care Up as AbbVie Rises on Earnings — Health Care Roundup |
Apr. 25 |
DJ |
|
Novavax Asked by FDA to Run Additional Trial on COVID-19 Vaccine |
Apr. 25 |
MT |
|
US FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports |
Apr. 25 |
RE |
|
FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports |
Apr. 25 |
RE |
NVAX: Dynamic Chart
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
More about the company
Buy
Average target price
15.29USD
Spread / Average Target
+127.13%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
